Perbedaan Organon Pharma Indonesia Tbk. dan Venteny Fortuna International Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Venteny Fortuna International Tbk. diperdagangkan di Rp72 (kapitalisasi pasar 476,15 M, volume 24 jam 21,68 jt). Perbedaan utamanya: Venteny Fortuna International Tbk. jauh lebih besar — sekitar 4,6× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | VTNY | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 476,15 M |
Volume | — | 21,68 jt |
Lot | — | 216,81 rb |
Perputaran | — | 1,59 M |
Harga Rata-rata | — | 73,22 |
Nilai Transaksi | — | 1,59 M |
Harga Ekuilibrium Indikatif | — | 72 |
Volume Ekuilibrium Indikatif | — | 4,89 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →PT Venteny Fortuna International Tbk (the Entity) was established based on Notarial Deed No. 7,dated January 29, 2021 of Anastasia Chandra, S.H., M.Kn., Notary in Tangerang. The Entity started its commercial operations in 2021. PT Venteny Fortuna International Tbk is the parent entity, whereas Junichiro Waide is the ultimate beneficial owner.
Selengkapnya di halaman VTNY →